Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2012: Volume 17/ Issue 17 Article 9
Back to Table of Contents
Previous

Eurosurveillance, Volume 17, Issue 17, 26 April 2012
Miscellaneous
Deadline for special issue on the molecular epidemiology of human pathogens extended to 30 June 2012

Citation style for this article: Deadline for special issue on the molecular epidemiology of human pathogens extended to 30 June 2012. Euro Surveill. 2012;17(17):pii=20160. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20160

Eurosurveillance invites authors to submit papers for a special issue on the molecular epidemiology of human pathogens.

The submission deadline has been extended to 30 June 2012.

As exemplified in the 2011 outbreak of the Shiga toxin-producing Escherichia coli (STEC) O104:H4 strain in Germany, advanced sequencing technologies are being introduced for application in microbiological investigations supporting surveillance and outbreak investigations. In the STEC outbreak, the traditional microbiological methods were used to characterise the outbreak strain for epidemiological investigations, but for the first time, parallel application of advanced technologies enabled the whole genome sequence of multiple isolates of the outbreak strain to be determined just a few days after the outbreak had been detected. While such scientific and technological advances have great potential to increase the resolution and accuracy of microbiological investigations and deepen our understanding of human pathogens and the diseases they cause, various operational issues need to be resolved in order for such advanced techniques to be incorporated into public health practice.

The aim of this special issue is to provide a comprehensive picture of the current thinking on the role and possible opportunities of applying modern molecular microbiology for informing public health action. It follows from the recent consultation organised by the European Centre for Disease Prevention and Control, which initiated discussion on how public health can benefit from the recent advances in molecular microbiology. We invite interested scientists and public health experts to share their findings and views and submit original papers for peer review and possible publication.

Topics of interest include, but are not limited to:

  • proof-of-principle examples of the use of advanced molecular methods, e.g. for the detection and characterisation of humans pathogens (bacteria, viruses, fungi and protozoa) and for understanding infectious disease dynamics;
  • issues related to the use of advanced molecular data on human pathogens for surveillance and outbreak investigation: future directions, potential limitations, needs and implications for public health.

If you would to submit a paper or ask for more information, please see our instructions for authors regarding article formats and contact the editorial team at eurosurveillance@ecdc.europa.eu.



Back to Table of Contents
Previous

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.